These strategies include co-administration of PD-1/PD-L1 inhibitors with CTLA-4 antagonists or integration with MDSC-depleting agents or tumor vaccines to overcome resistance and enhance antitumor immunity [61]. This evidence concerns the gene CD274 and neoplasm.